AU Patent

AU2014299447B2 — Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin

Assigned to Hanmi Pharmaceutical Co Ltd · Expires 2019-01-17 · 7y expired

What this patent protects

Disclosed are a capsule composite formulation for preventing or treating erectile dysfunction and benign prostatic hyperplasia comprising tadalafil and tamsulosin, and a method of preparing the same. The capsule composite formulation of the present invention enables the complete …

USPTO Abstract

Disclosed are a capsule composite formulation for preventing or treating erectile dysfunction and benign prostatic hyperplasia comprising tadalafil and tamsulosin, and a method of preparing the same. The capsule composite formulation of the present invention enables the complete separation of the two pharmaceutically active ingredients and minimizes reactivity between the active ingredients, and thus provides excellent product stability over time, thereby maximizing the therapeutic effects thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014299447B2
Jurisdiction
AU
Classification
—
Expires
2019-01-17
Drug substance claim
No
Drug product claim
No
Assignee
Hanmi Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.